首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Aristolochic acid nephropathy in a Chinese patient: time to abandon the term 'Chinese herbs nephropathy'?
【24h】

Aristolochic acid nephropathy in a Chinese patient: time to abandon the term 'Chinese herbs nephropathy'?

机译:中国患者的马兜铃酸肾病:该放弃“中药肾病”一词了吗?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The causal role of aristolochic acid (AA) in the so-called Chinese herbs nephropathy (CHN) has been conclusively demonstrated only in the Belgian epidemic. We report a biopsy-proven hypocellular interstitial fibrosing nephropathy in a Chinese patient who had ingested a Chinese herbal preparation bought in Shanghai. The identification of AA in the preparation and of AA-DNA adducts in the kidney tissue unequivocally demonstrates, for the first time, the causal role of AA outside the Belgian epidemic. Because the ingested preparation is very popular in China as an over-the-counter product, our observation raises the possibility that many such cases due to AA might be currently unrecognized in China. AA should be banned from herbal preparations worldwide. All cases of the so-called CHN, in which the causal role of AA has been thoroughly documented, should be further identified as aristolochic acid nephropathy (AAN). The term phytotherapy-associated interstitial nephritis (PAIN) might refer to the other cases associated with phytotherapy without identification, as yet, of the causal agent.
机译:马兜铃酸(AA)在所谓的中药肾病(CHN)中的因果作用仅在比利时流行病中得到了确证。我们报道了一名中国患者经活检证实的细胞间质纤维化性肾病,该患者摄入了在上海购买的中草药。制剂中AA的鉴定以及肾脏组织中AA-DNA加合物的鉴定明确地首次证明了AA在比利时流行病之外的因果作用。由于摄取的制剂作为非处方产品在中国非常受欢迎,因此我们的观察结果提出了许多这样的可能性,即在中国目前可能无法识别出许多由于AA引起的病例。全世界的草药制剂均应禁止使用AA。彻底记录了AA的因果作用的所有所谓CHN病例,应进一步鉴定为马兜铃酸肾病(AAN)。与植物疗法相关的间质性肾炎(PAIN)一词可能是指与植物疗法相关的其他病例,但尚未确定病因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号